ArticleThe Journal of clinical endocrinology and metabolism1997
Growth hormone (GH) retesting and auxological data in 131 GH-deficient patients after completion of treatment.
Article in The Journal of clinical endocrinology and metabolism, 1997. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01237041 (Free Fatty Acids, Body Weight, and Growth Hormone Secretion in Children), which is not on this map. Cited by 38 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Free Fatty Acids, Body Weight, and Growth Hormone Secretion in Children
Open the trial in the graphWho cites it
38 citing papers in PubMed, 1 synthesis or guideline pooled it, 205 citations in OpenAlex.
- Sex steroid priming for growth hormone stimulation testing in children and adolescents with short stature: A systematic review.Clinical endocrinology · 2023Pooled it
- Growth hormone retesting for idiopathic isolated growth hormone deficiency during and after puberty: a systematic review.Journal of the Endocrine Society · 2026Review
- Sex Steroid Priming on Growth Hormone Stimulation Test: A Scoping Review.Children (Basel, Switzerland) · 2025Review
- Accuracy of Glucagon Testing Across Transition in Young Adults With Childhood-Onset GH Deficiency.The Journal of clinical endocrinology and metabolism · 2024Article
- Transient Isolated, Idiopathic Growth Hormone Deficiency-A Self-Limiting Pediatric Disease with Male Predominance or a Diagnosis Based on Uncertain Criteria? Lesson from 20 Years' Real-World Experience with Retesting at One Center.International journal of molecular sciences · 2024Article
- Optimal final adult height achieved by low-dose recombinant human growth hormone therapy.Asian biomedicine : research, reviews and news · 2024Article
- Evolving growth hormone deficiency: proof of concept.Frontiers in endocrinology · 2024Article
- Policy for transitioning childhood-onset growth hormone deficiency from pediatric to adult endocrine care in Belgium.Frontiers in endocrinology · 2024Review
- Identifying patient-related predictors of permanent growth hormone deficiency.Frontiers in endocrinology · 2023Article
- Efficacy of short-term induction therapy with low-dose testosterone as a diagnostic tool in the workup of delayed growth and puberty in boys.Journal of endocrinological investigation · 2022Article
- Approach to the Patient: Management of Pituitary Hormone Replacement Through Transition.The Journal of clinical endocrinology and metabolism · 2022Article
- Influence of biochemical diagnosis of growth hormone deficiency on replacement therapy response and retesting results at adult height.Scientific reports · 2021Article
- Effectiveness, economical and safety aspects of growth hormone (GH) therapy in growth promoting doses in patients with isolated GH deficiency after the attainment of near-final height. Is there a need to modify the criteria of therapy withdrawal?Pediatric endocrinology, diabetes, and metabolism · 2021Article
- Impact of BMI on peak growth hormone responses to provocative tests and therapeutic outcome in children with growth hormone deficiency.Scientific reports · 2019Observational
- Bone microarchitecture and volumetric bone density impairment in young male adults with childhood-onset growth hormone deficiency.European journal of endocrinology · 2019Article
- Growth Hormone (GH) Therapy During the Transition Period: Should We Think About Early Retesting in Patients with Idiopathic and Isolated GH Deficiency?International journal of environmental research and public health · 2019Article
- Relevance of Pituitary Gland Magnetic Resonance Imaging Results with Clinical and Laboratory Findings in Growth Hormone Deficiency.Medical science monitor : international medical journal of experimental and clinical research · 2018Article
- Transcriptomic Changes in Broiler Chicken Hypothalamus during Growth and Development.International journal of genomics · 2018Article
- Managing Transition in Patients Treated with Growth Hormone.Frontiers in endocrinology · 2017Article
- Update on GH therapy in adults.F1000Research · 2017Review
Corrections and comments
- Commented on by
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
GH state and auxological data after completion of GH therapy are reported in 131 patients (79 males, 52 females). They were treated from 1980-1994 for partial (n = 98) or complete (n = 33) GH deficiency (GHD), either idiopathic (n = 121) or organic (n = 10). A single stimulation test (clonidine+betaxolol) was used, and only 50 patients (38%) maintained a blunted response (GH peak below 10 micrograms/L). Although 9 of the 10 patients with organic GHD had an abnormal low GH peak, 67% of patients with idiopathic GHD normalized their GH secretion. This was particularly true of partial GHD patients (71% vs. 36% of complete GH-deficient patients). Based on a retest GH peak below 5 micrograms/L, only 23% of the patients were considered to be GH deficient and therefore candidates for GH treatment during adulthood. We found no significant difference between hormonal state at completion of treatment and initial GH deficiency, pubertal state, or sex, although we did find a significantly lower GH peak value before and after treatment in patients with elevated body mass index. Of the 14 obese children who were treated, 50% had an abnormally low serum insulin-like growth factor-I level, arguing for true GHD, and only two children remained obese at cessation of treatment. Auxological data showed that with a mean duration of treatment of 3.6 +/- 2.0 yr, patients classified as having complete GHD before treatment had significantly greater catch-up growth as expressed in SDS for height than patients with partial GHD (0.6 +/- 1.1 vs. 1.1 +/- 0.7 SDS, P < 0.05), and that boys grew better than girls (1.4 +/- 0.8 vs. 1.6 +/- 0.6 SDS) for height, P < 0.01). That catch-up growth was not correlated with the result of GH peak after cessation of treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.